Aligning patient-centric approaches with personalized medicine and biomarker use is transforming the design of Alzheimer's trials.
John Hubbard, PhD
Advertisement
Articles by John Hubbard, PhD
Advertisement
Latest Updated Articles
Lightship’s Approach to Accessible, Representative, and Impactful Clinical TrialsPublished: February 13th 2025 | Updated: March 4th 2025
Accelerate Inclusive Enrollment and Delivery with LightshipPublished: February 19th 2025 | Updated: February 26th 2025
Examining the Impact of Exclusionary Behaviors on Team DynamicsPublished: March 24th 2023 | Updated:
Trials and Tribulations of Electronic Patient Consent: Removing Barriers to eConsent AdoptionPublished: April 28th 2021 | Updated:
Sticking to the Plan: Undue Burden Created by Protocol DeviationsPublished: July 26th 2024 | Updated:
Phase III PERSEUS Trial Data Show Darzalex Faspro Combo Improves Survival in Newly Diagnosed Multiple MyelomaPublished: January 31st 2024 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Using AI Trial-Matching Tools to Accelerate Patient Access
2
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
3
Beyond the Algorithm: How Human-Centered AI Design Can Drive Clinical Trial Success
4
ACT Brief Episode 7: Veeva and Merck Trial Efficiency, DCT Barriers, and Glucose Monitoring Strategies
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
